BioMarin Pharmaceutical Inc.

NasdaqGS:BMRN Stock Report

Market Cap: US$10.3b

BioMarin Pharmaceutical Dividends and Buybacks

Dividend criteria checks 0/6

BioMarin Pharmaceutical does not have a record of paying a dividend.

Key information

n/a

Dividend yield

0.4%

Buyback Yield

Total Shareholder Yield0.4%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts

Oct 30
Earnings Miss: BioMarin Pharmaceutical Inc. Missed EPS And Analysts Are Revising Their Forecasts

BioMarin Pharmaceuticals - Growing Numbers, Falling Expectations

Oct 28

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 06
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Jul 22
Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment?

Apr 27
Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment?

The Price Is Right For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Mar 31
The Price Is Right For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

The Strong Earnings Posted By BioMarin Pharmaceutical (NASDAQ:BMRN) Are A Good Indication Of The Strength Of The Business

Mar 04
The Strong Earnings Posted By BioMarin Pharmaceutical (NASDAQ:BMRN) Are A Good Indication Of The Strength Of The Business

BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 21
BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

BioMarin Pharmaceuticals: Share Downdraft Combined With VOXZOGO Potential Makes A Buy

Jan 23

Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet?

Dec 26
Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet?

Biomarin: Challanges Mount, But Sale Rumours Make For A Risky "Buy" Call

Nov 21

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar

Nov 14
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar

BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024

Aug 21

BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024

Jul 24

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

May 15

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Feb 29

BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?

Jan 19

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if BMRN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMRN's dividend payments have been increasing.

Dividend Yield vs Market

BioMarin Pharmaceutical Dividend Yield vs Market
How does BMRN dividend yield compare to the market?
SegmentDividend Yield
Company (BMRN)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.6%
Industry Average (Biotechs)2.2%
Analyst forecast (BMRN) (up to 3 years)0%

Notable Dividend: Unable to evaluate BMRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BMRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate BMRN's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BMRN has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/02 10:48
End of Day Share Price 2025/10/31 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioMarin Pharmaceutical Inc. is covered by 50 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Ying HuangBarclays
Huidong WangBarclays